Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1231results about "Peptide-nucleic acids" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
Owner:JEAN LOUIS DASSEUX +5
Stabilized compounds having secondary structure motifs
InactiveUS7192713B1Peptide-nucleic acidsGroup 8/9/10/18 element organic compoundsCrystallographyCarbon–carbon bond
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.
Owner:SOMALOGIC INC
Histidine copolymer and methods for using same
InactiveUS7163695B2Prolong half-life in vivoEnhanced transfectionPowder deliveryPeptide/protein ingredientsHistidine residueCopolymer
The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.
Owner:MIXSON A JAMES
Branched histidine copolymers and methods for using same
InactiveUS7070807B2Prolong half-life in vivoEnhanced transfectionPowder deliveryPeptide/protein ingredientsIn vivoLocal injection
Owner:MIXSON A JAMES
Proteinaceous pharmaceuticals and uses thereof
InactiveUS20070191272A1High disulfide densityReduce molecular weightPeptide librariesNervous disorderCysteine thiolateBiology
The present invention provides cysteine-containing scaffolds and / or proteins, expression vectors, host cell and display systems harboring and / or expressing such cysteine-containing products. The present invention also provides methods of designing libraries of such products, methods of screening such libraries to yield entities exhibiting binding specificities towards a target molecule. Further provided by the invention are pharmaceutical compositions comprising the cysteine-containing products of the present invention.
Owner:AMUNIX OPERATING INC
Methods for production of unstructured recombinant polymers and uses thereof
ActiveUS20080286808A1Extended half-lifePeptide/protein ingredientsAntibody mimetics/scaffoldsToxinPolymer
Owner:AMUNIX PHARMA INC
Modified antibody compositions, methods of making and using thereof
InactiveUS20100189651A1Reduce capacityNervous disorderAntibody mimetics/scaffoldsAntibody fragmentsChemistry
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Owner:CYTOMX THERAPEUTICS
Nucleic acid modifying enzymes
This invention provides for an improved generation of novel nucleic acid modifying enzymes. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.
Owner:BIO RAD LAB INC
Apparatus and method for automated protein design
The present invention relates to apparatus and methods for quantitative protein design and optimization.
Owner:CALIFORNIA INST OF TECH
Risperidone immunoassay
Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
Owner:SALADAX BIOMEDICAL INC
Triazole Macrocycle Systems
InactiveUS20080262200A1Simple structureExhibit biological activityPeptide-nucleic acidsTumor rejection antigen precursorsCombinatorial chemistryAmino acid
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
Owner:AILERON THERAPEUTICS INC
Cell penetrating peptides
InactiveUS8575305B2Increase serum stabilityMinimising immunogenicityOrganic active ingredientsNervous disorderComputational chemistryCell-penetrating peptide
Owner:UK RES & INNOVATION LTD
Mutant protein
InactiveUS20060194950A1Improve stabilityIncreased pH-valuesBacteriaSerum immunoglobulinsMutated proteinComplementarity determining region
Owner:GE HEALTHCARE BIO SCI CORP
Mutated immunoglobulin-binding protein
ActiveUS20050143566A1Improve stabilityIncreased pH-valuesSerum immunoglobulinsComponent separationComplementarity determining regionChemical stability
The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
Owner:CYTIVA BIOPROCESS R&D AB
Apparatus and method for automated protein design
Owner:MAYO STEPHEN +4
Methods for production of unstructured recombinant polymers and uses thereof
Owner:AMUNIX PHARMA INC
Modified Antibody Compositions, Methods of Making and Using Thereof
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Owner:CYTOMX THERAPEUTICS
Peptidomimetic macrocycles with improved properties
ActiveUS20100298201A1Prolong half-life in vivoHalogenated hydrocarbon active ingredientsNervous disorderBioactive peptideBiological organism
The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
Owner:AILERON THERAPEUTICS INC
Specific binding agents of human angiopoietin-2
Owner:AMGEN INC
Proteins Toxic To Hemipteran Insect Species
The present invention discloses Hemipteran insect inhibitory proteins, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
Owner:MONSANTO TECH LLC
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
InactiveUS7074580B2Accurate and robust calibration setTherapeutic utilityPeptide/protein ingredientsDisease diagnosisRetention timeLinear relationship
The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers using molecular weight markers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases.
Owner:YEDA RES & DEV CO LTD
Insect Inhibitory Toxin Family Active Against Hemipteran and/or Lepidopteran Insects
The present invention discloses a genus of insect inhibitory proteins that exhibit properties directed to controlling Lepidopteran and / or Hemipteran crop pests, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
Owner:MONSANTO TECH LLC
Sustained delivery of PDGF using self-assembling peptide nanofibers
InactiveUS20060148703A1Improve membrane permeabilityReduce deathPeptide/protein ingredientsMuscular disorderMedicineSelf-assembling peptide
The present invention is directed to a therapeutic composition in which human PDGF is bound directly to peptides that self assemble into a biologically compatible gel. When implanted in a patient's body, the composition provides for the slow, sustained release of PDGF. The composition will be especially useful in treating patients who have undergone a myocardial infarction.
Owner:THE BRIGHAM & WOMENS HOSPITAL INC
Targeted delivery of biological factors using self-assembling peptide nanofibers
InactiveUS20060088510A1Prevent bacterial growthBiocidePeptide/protein ingredientsTissue repairIn vivo
The present invention is directed to methodology that allows a variety of compounds to be attached to self-assembling peptides using biotin / streptavidin linkages. The peptides can be used to form a biologically compatible membrane that promotes the growth and differentiation of cells. The attached therapeutic agents can be used to promote this process and the gel along with the growing cells can be implanted at a site in vivo where tissue repair is needed. Alternatively, membranes can be used for culturing cells in vitro or can be used for delivering drugs in vivo in the absence of seeded cells.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Isolating biological modulators from biodiverse gene fragment libraries
InactiveUS6994982B1Increase diversityEasy to controlPeptide-nucleic acidsPeptide librariesExpression LibraryNucleotide
The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of:(i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and(ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.
Owner:PHYLOGICA
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
InactiveUS20060040882A1Increase serum stabilityPreserve RNAi activity in cellsOrganic active ingredientsSpecial deliveryRegulator genePolynucleotide
Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference (RNAi). The siNA / polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA / polypeptide compositions are administered.
Owner:MDRNA
Method for identifying hair conditioner-resistant hair-binding peptides and hair benefit agents therefrom
A method for identifying hair conditioner-resistant hair-binding peptides is described. The hair conditioner-resistant hair-binding peptides bind strongly to hair from a hair conditioner matrix and are stable therein. Peptide-based benefit agents, such as hair conditioners and hair colorants, based on the hair conditioner-resistant hair binding peptides are described. The peptide-based hair conditioners and hair colorants consist of a hair conditioner-resistant hair-binding peptide coupled to a hair conditioning agent or a coloring agent, either directly or through an optional spacer. Hair care and hair coloring product compositions comprising these peptide-based hair conditioners and colorants are also described.
Owner:EI DU PONT DE NEMOURS & CO
Conformationally constrained backbone cyclized peptide analogs
Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are Nα(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these Nα(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.
Owner:DEVELOGEN ISRAEL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com